Novo Nordisk A/S Common Stock (NY:NVO)

37.06 -0.26 (-0.69%)

Delayed Quote Updated: 11:56 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

99 100 Next >

Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge ↗

November 03, 2025

Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.

Via Investor's Business Daily

Hims & Hers Stock Pops After Q3 Earnings: Here's Why ↗

November 03, 2025

Here's a look at the Q3 earnings report from Hims & Hers Health.

Via Benzinga

Did Novo Nordisk Just Say "Checkmate" to Pfizer? ↗

November 03, 2025

These two leading drugmakers are fighting over a promising GLP-1 candidate.

Via The Motley Fool

Topics Intellectual Property

Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo ↗

November 03, 2025

Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.

Via Investor's Business Daily

Topics Economy Lawsuit

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle ↗

November 03, 2025

Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal.

Via Benzinga

Topics Lawsuit

The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit ↗

November 03, 2025

Via Stocktwits

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗

October 30, 2025

Via Stocktwits

Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer ↗

October 30, 2025

Via Stocktwits

2 Beaten-Down Stocks That Could Be About to Rally ↗

November 03, 2025

It would be best to get in before the rest of the market pounces on these opportunities.

Via The Motley Fool

Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health ↗

November 03, 2025

Novo Nordisk (NVO) is a top dividend stock with a 3.6% yield, strong growth, and a sustainable payout backed by exceptional profitability and financial health.

Via Chartmill

Should You Buy Viking Therapeutics Before Nov. 5? ↗

November 02, 2025

Viking's stock surged in one trading session after a positive clinical trial report last year.

Via The Motley Fool

Is It Time to Dump Your Shares of Pfizer? ↗

November 02, 2025

Pfizer stock has dropped 50% over the past three years.

Via The Motley Fool

Topics Intellectual Property

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal ↗

October 31, 2025

Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.

Via Investor's Business Daily

Topics Law Enforcement Lawsuit

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗

October 31, 2025

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Via Stocktwits

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

P/E Ratio Insights for Novo Nordisk ↗

October 24, 2025

Via Benzinga

Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera ↗

October 30, 2025

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Via Investor's Business Daily

Topics Economy Government

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' ↗

October 30, 2025

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.

Via Benzinga

1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner ↗

October 29, 2025

It offers compelling weight-loss drugs -- and a compelling stock price, too.

Via The Motley Fool

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried? ↗

October 29, 2025

It's not the end of the world for the drugmaker.

Via The Motley Fool

Topics Government Intellectual Property

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These ↗

October 28, 2025

These two have been neglected by Wall Street too much.

Via The Motley Fool

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

What Is 1 of the Best Pharmaceutical Stocks to Buy Now? ↗

October 27, 2025

This pharma giant is entering the rapidly expanding market for weight loss drugs.

Via The Motley Fool

Viking Therapeutics: High Risk, High Reward Play ↗

October 27, 2025

Via MarketBeat

Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk ↗

October 23, 2025

While Novo Nordisk has been victimized by broader market pressure, NVO stock has just flashed a reliable quant signal for bullish traders.

Via Benzinga

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership ↗

October 23, 2025

Via Benzinga

Topics Initial Public Offering

Breakout Momentum Plays You Need to Know About ↗

October 23, 2025

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

Via MarketBeat

Weight Loss Drugs Are Quietly Exploding Employer Health Insurance Costs: 'There Is A Quiet Alarm Bell Going Off' ↗

October 23, 2025

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending.

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.